Here are the 10-K annual reports from MaxCyte, Inc. (MXCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MXCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MXCT filings page.
MaxCyte, Inc. is a commercial cell engineering company whose ExPERT Flow Electroporation platform underpins next-generation cell and gene therapy research, clinical development and manufacturing. The product family spans five instruments plus proprietary processing assemblies, consumables and GMP electroporation buffer, with more than 857 instruments installed globally.
The company focuses on Strategic Platform Licenses, or SPLs, that pair annual instrument fees with potential precommercial milestones and commercial sales-based payments. MaxCyte reports 33 SPL agreements, 31 active, with 13 clinical programs as of December 31, 2025. These SPLs have potential to generate more than $2 billion, including over $130 million in precommercial milestone opportunities from active clinical programs, of which more than $30 million has been realized so far.
In January 2025, MaxCyte acquired SeQure Dx, adding on- and off-target gene-editing assessment assays and services to support ex vivo and in vivo therapy developers. The company remains loss-making, with a 2025 net loss of $44.6 million and an accumulated deficit of $261.5 million as of December 31, 2025. Research and development expenses were $20.8 million in 2025 and $22.2 million in 2024, reflecting continued investment in platform innovation. Management highlights dependence on biopharmaceutical R&D spending, milestone timing under SPLs, competition from other non-viral delivery and electroporation providers, and regulatory and data-privacy obligations as key risks.